Nuvalent (NUVL) Net Income towards Common Stockholders (2020 - 2026)
Nuvalent (NUVL) posted Net Income towards Common Stockholders of -$109.3 million for Q1 2026, down 277.94% on a QoQ basis from -$28.9 million in Q4 2025, and down 29.2% year-over-year from -$154.3 million in Q1 2025.
Nuvalent (NUVL) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Nuvalent's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$109.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 29.2% year-over-year to -$109.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$360.3 million (down 19.75% YoY) and the FY2025 annual result came in at -$335.6 million, down 28.7% from the prior year.
- Net Income towards Common Stockholders was -$109.3 million for Q1 2026 at Nuvalent, down from -$28.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$18.6 million in Q1 2022 and bottomed at -$122.4 million in Q3 2025.
- A 5-year average of -$54.0 million and a median of -$38.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 201.38% — and 2025, when it soared 61.33%.
- Nuvalent's Net Income towards Common Stockholders stood at -$27.5 million in 2022, then tumbled by 39.44% to -$38.3 million in 2023, then tumbled by 95.24% to -$74.8 million in 2024, then surged by 61.33% to -$28.9 million in 2025, then plunged by 277.94% to -$109.3 million in 2026.
- Business Quant data shows NUVL's Net Income towards Common Stockholders at -$109.3 million in Q1 2026, -$28.9 million in Q4 2025, and -$122.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -109.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.28 Mn |
| Dec 31, 2025 | -28.91 Mn |
| Sep 30, 2025 | -122.44 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -74.76 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -27.46 Mn |
| Sep 30, 2022 | -20.58 Mn |
| Jun 30, 2022 | -19.60 Mn |
| Mar 31, 2022 | -18.57 Mn |
| Dec 31, 2021 | -40.78 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |